Page last updated: 2024-11-13
J147
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
J147: neurotrophic curcumin derivative compound that has enhanced stability and bioavailability over curcumin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 25229652 |
CHEMBL ID | 2387144 |
CHEBI ID | 192601 |
SCHEMBL ID | 12995834 |
SCHEMBL ID | 21294999 |
Synonyms (37)
Synonym |
---|
n-(2,4-dimethylphenyl)-2,2,2-triluoro-n-[(e)-(3-methoxyphenyl)methylideneamino]acetamide |
1807913-16-1 |
CHEBI:192601 |
j147 |
j-147 |
CHEMBL2387144 |
S5269 |
CS-3688 |
SCHEMBL12995834 |
1146963-51-0 |
2,2,2-trifluoroacetic acid 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide |
AC-35232 |
HY-13779 |
AKOS024458485 |
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-[(3-methoxyphenyl)methylidene]acetohydrazide |
mfcd25976644 |
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-[(1e)-(3-methoxyphenyl)methylidene]acetohydrazide |
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-(3-methoxybenzylidene)acetohydrazide |
EX-A2235 |
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-[(e)-(3-methoxyphenyl)methylene]acetohydrazide |
DB13957 |
AS-16718 |
SCHEMBL21294999 |
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n-[(e)-(3-methoxyphenyl)methylideneamino]acetamide |
acetic acid, 2,2,2-trifluoro-, (2e)-1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide |
unii-z41h3c5bt9 |
acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide |
Z41H3C5BT9 , |
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n-((e)-(3-methoxyphenyl)methylideneamino)acetamide |
acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide |
HMS3886O17 |
CCG-268030 |
(e)-n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-(3-methoxybenzylidene)acetohydrazide |
A894156 |
hymzaygfknnhdn-ssdvnmtosa-n |
DTXSID501045787 |
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-[(e)-(3-methoxyphenyl)methylidene]acetohydrazide |
Research Excerpts
Overview
J147 is a novel drug candidate developed to treat neurological dysfunction.
Excerpt | Reference | Relevance |
---|---|---|
"J147 is a novel drug candidate developed to treat neurological dysfunction. " | ( The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver. Currais, A; Fischer, W; Huang, L; Kepchia, D; Liang, Z; Maher, P, 2022) | 2.43 |
Treatment
Excerpt | Reference | Relevance |
---|---|---|
"J147 pretreatment markedly downregulated expression of IL-6, IL-1β, and TNF-α, and the mean fluorescence intensity of ionized calcium-binding adapter protein-1 in microglia." | ( J147 ameliorates sepsis-induced depressive-like behaviors in mice by attenuating neuroinflammation through regulating the TLR4/NF-κB signaling pathway. Ke, C; Liu, Y; Pan, H; Qiu, F; Zeng, C, 2023) | 3.07 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
anilide | Any aromatic amide obtained by acylation of aniline. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (29)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID748848 | Drug metabolism in mouse liver microsomes assessed as (E)-2,2,2-trifluoro-N-(4-(hydroxymethyl)-2-methylphenyl)-N'-(3-methoxybenzylidene)acetohydrazide retention time at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748865 | Drug metabolism in human liver microsomes assessed as formation of (E)-N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-(3-hydroxybenzyli-dene)acetohydrazide at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748853 | Half life in human liver microsomes at 5 uM by LC/MS/MS analysis in presence of NADPH | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748876 | Drug metabolism in mouse liver microsomes assessed as metabolite M5 retention time at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748864 | Drug metabolism in human liver microsomes assessed as formation of (E)-2,2,2-trifluoro-N-(4-(hydroxymethyl)-2-methylphenyl)-N'-(3-methoxybenzylidene)acetohydrazide at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748872 | Drug metabolism in human liver microsomes assessed as formation of 3-methoxy benzaldehyde at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748851 | Drug metabolism in human liver microsomes assessed as retention time at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748862 | Half life in BALB/c mouse blood at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748863 | Half life in BALB/c mouse brain at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748861 | Drug metabolism in BALB/c mouse blood assessed as retention time at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748857 | Neuroprotective activity in rat primary cortical neurons assessed as reduction in trophic factor withdrawal after 2 days by fluorescent live-dead assay | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748873 | Drug metabolism in human liver microsomes assessed as formation of 2,4-dimethylhydrazine at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748849 | Drug metabolism in mouse liver microsomes assessed as (E)-N'-(3,4-dihydroxybenzylidene)-N-(2,4-dimethylphenyl)-2,2,2-trifluoroacetohydrazide retention time at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748854 | Half life in mouse liver microsomes at 5 uM by LC/MS/MS analysis in presence of NADPH | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748874 | Drug metabolism in human liver microsomes assessed as formation of 2,4-dimethylaniline at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748858 | Drug metabolism in BALB/c mouse blood assessed as (E)-N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-(3-hydroxybenzyli-dene)acetohydrazide retention time at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748852 | Drug metabolism in mouse liver microsomes assessed as retention time at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748869 | Drug metabolism in mouse liver microsomes assessed as formation of 3-methoxy benzaldehyde at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748866 | Drug metabolism in mouse plasma assessed as formation of 2,4-dimethylhydrazine at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748860 | Drug metabolism in BALB/c mouse blood assessed as metabolite BM1 retention time at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748868 | Drug metabolism in mouse plasma assessed as formation of 2,4-dimethylaniline at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748856 | Neuroprotective activity in human MC65 cells expressing C-terminal 99 amino acids from beta secretase assessed as reduction in intracellular amyloid beta toxicity after 4 days by MTT assay | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748859 | Drug metabolism in BALB/c mouse blood assessed as metabolite BM2 retention time at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748871 | Drug metabolism in mouse liver microsomes assessed as formation of 2,4-dimethylhydrazine at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748850 | Drug metabolism in mouse liver microsomes assessed as (E)-N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-(3-hydroxybenzyli-dene)acetohydrazide retention time at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748870 | Drug metabolism in mouse liver microsomes assessed as formation of 2,4-dimethylaniline at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748875 | Drug metabolism in mouse liver microsomes assessed as metabolite M4 retention time at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748867 | Drug metabolism in mouse plasma assessed as formation of 3-methoxy benzaldehyde at 5 uM by LC/MS/MS analysis | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
AID748855 | Neuroprotective activity in mouse HT22 cells assessed as reduction in glutamate-induced oxidative stress incubated for 30 mins prior to glutamate-challenge measured after 24 hrs by MTT assay | 2013 | Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10 | Metabolism of a potent neuroprotective hydrazide. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (36.36) | 24.3611 |
2020's | 7 (63.64) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 31.09
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.09) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (18.18%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (81.82%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |